Weight Loss, Less Hunger Sustained with Setmelanotide in 2 Rare Forms of Genetic Obesity, Phase 2/3 Trial Shows
Treatment with setmelanotide continues to provide significant weight loss at two years in six of nine patients with Bardet-Biedl syndrome (BBS) taking part in an ongoing Phase 2/3 basket trial. Also, five patients have experienced a significant decrease in hunger. These findings support previously reported results by…